Our CpG-siRNA conjugate services support biotechnology companies, pharmaceutical research teams, CROs, and academic laboratories developing targeted RNA interference tools for TLR9-positive immune-cell models. A CpG-siRNA conjugate combines an immunostimulatory CpG oligodeoxynucleotide with an siRNA duplex so that receptor-associated uptake, intracellular processing, and sequence-specific gene silencing can be studied within one defined construct. Successful programs require more than joining two oligonucleotides: the CpG motif, backbone pattern, siRNA architecture, attachment site, linker length, purification method, and functional assay plan must be designed as an integrated system.
Our platform coordinates CpG ODN selection, siRNA design, strand-level modification planning, conjugation chemistry, purification, duplex preparation, analytical characterization, and research-stage functional evaluation. We help clients build well-defined CpG-siRNA constructs for uptake studies, TLR9 pathway research, Dicer-processing investigations, and gene-silencing experiments in suitable cell and animal research models, with deliverables structured for technical review and next-step decision-making.
Target-Cell and Species Fit: CpG-mediated delivery depends on the biological model, TLR9 expression, receptor localization, and species-specific CpG recognition. A sequence that performs well in one immune-cell system may not translate directly to another. We review the intended cell type, species, CpG class, and assay context before chemistry is finalized so that the construct is aligned with the actual uptake and signaling question.
Balancing CpG Activity and RNAi Performance: The CpG domain must retain useful TLR9-related activity while the siRNA domain preserves guide-strand loading and target-mRNA recognition. Excessive backbone modification, poorly placed conjugation handles, or an unsuitable duplex design can distort one function while preserving the other. Our design process evaluates both modules together rather than treating the CpG ODN as a simple delivery tag.
Dicer Processing and Intracellular Release: Many CpG-siRNA studies use Dicer-substrate architectures to enable intracellular processing of a longer duplex into an active siRNA species. Conjugation position, duplex polarity, overhang design, spacer length, and local chemical modifications can influence cleavage and downstream RNAi activity. We plan the construct around the intended processing mechanism and recommend direct testing when Dicer-dependent release is central to the project.
Mixed DNA/RNA Chemistry and Purification: CpG-siRNA conjugates combine chemically distinct nucleic acid domains and may contain phosphorothioate linkages, modified riboses, terminal handles, and flexible spacers. Incomplete coupling, closely eluting truncations, free CpG ODN, unconjugated siRNA strands, and annealing imbalance can complicate purification. We select synthesis, conjugation, and purification workflows according to the full construct rather than relying on a standard oligonucleotide process.
Functional Evidence Beyond Identity: Molecular mass and chromatographic purity confirm that a material was produced, but they do not establish receptor-associated uptake, CpG activity, intracellular processing, or gene silencing. Our programs can connect oligonucleotide characterization with uptake, pathway-response, Dicer-processing, and siRNA interference detection studies so that research teams can distinguish chemical success from functional success.
Our CpG-siRNA conjugate services cover the coordinated work needed to move from a biological concept to a purified and analytically defined research construct. Project scope can begin with an existing CpG and siRNA sequence or include complete sequence review, chemistry selection, conjugate assembly, analytical testing, and functional comparison.
Each program is planned around the intended TLR9-positive model, the desired relationship between immune-receptor signaling and RNAi, and the level of evidence required for candidate selection. Related capabilities can be integrated through our siRNA conjugate services, CpG ODN synthesis, and broader oligonucleotide conjugation services.
CpG-siRNA conjugate performance is governed by interacting design variables rather than a single preferred format. The matrix below summarizes practical choices that influence receptor engagement, intracellular processing, RNAi activity, synthetic feasibility, and the controls required for interpretation.
| Design Element | Common Options | Primary Decision Question | Main Development Risk | Recommended Checkpoint |
| CpG Sequence Context | Species-matched CpG motifs; class A-, B-, or C-like research designs; custom motif arrangements | Which CpG architecture best matches the species, TLR9-positive cell type, and desired signaling profile? | Weak activity, excessive pathway response, or poor translation between model systems | CpG-only control and species-matched TLR9 response assay |
| CpG Backbone | Phosphodiester, full phosphorothioate, or mixed-backbone configurations | How much stability is needed without creating unwanted protein binding or altered receptor behavior? | Instability, nonspecific interactions, altered uptake, or changed cytokine profile | Identity, purity, stability, and functional comparison across backbone variants |
| siRNA Architecture | Conventional 21-mer duplex, asymmetric duplex, or 25/27-mer Dicer-substrate siRNA | Should the conjugate function directly as a short siRNA or depend on intracellular Dicer processing? | Reduced RISC loading, inefficient processing, or passenger-strand activity | Unconjugated siRNA control, Dicer-processing assay, and knockdown comparison |
| Attachment Site | 5′ or 3′ terminal attachment on the selected siRNA strand; terminal CpG attachment | Which junction preserves guide-strand function and provides the intended processing geometry? | Steric interference with Dicer, Ago loading, duplex stability, or CpG recognition | Side-by-side terminal variants and strand-specific sequence map review |
| Linker Strategy | Direct linkage, C3/C6-type spacer, PEG-like spacer, disulfide, or click-derived junction | Is simple separation sufficient, or is triggered release required for the research hypothesis? | Conjugate rigidity, premature cleavage, poor release, aggregation, or analytical heterogeneity | Conjugate-integrity testing, processing study, and linker-control construct |
| siRNA Modifications | 2′-OMe, 2′-F, terminal phosphorothioates, phosphorylation, overhang, or end-blocking patterns | How can nuclease resistance and strand bias be improved without blocking Dicer or RISC compatibility? | Overstabilization, impaired cleavage, reduced potency, or altered innate-sensing background | Modified versus minimally modified duplex comparison |
| Control Set | CpG alone, siRNA alone, unconjugated mixture, non-CpG ODN conjugate, non-targeting siRNA conjugate, linker control | Which component is responsible for uptake, signaling, processing, and silencing? | Incorrect attribution of effects to the conjugate mechanism | Predefined control matrix covering chemistry and biology |
A useful development package should establish what was synthesized, whether the duplex and junction remain intact, how the construct behaves in the selected biological model, and whether observed silencing can be separated from CpG-driven pathway effects. The evaluation plan below can be tailored to candidate-screening or mechanism-focused programs.
| Evaluation Category | Purpose | Typical Methods | Key Output | Decision Supported |
| Molecular Identity | Confirm the expected CpG domain, siRNA strands, and final covalent construct | Mass spectrometry, sequence documentation, conjugation-junction review | Expected versus observed molecular species | Whether the intended construct was successfully produced |
| Purity Profile | Resolve full-length conjugate from free strands, truncations, and coupling byproducts | Ion-pair reversed-phase HPLC, anion-exchange HPLC, or other fit-for-purpose chromatography | Main peak, related species, and comparative purity profile | Whether material is suitable for downstream comparative studies |
| Duplex Integrity | Verify strand pairing and detect incomplete annealing or aggregation | Native electrophoresis, size-based separation, thermal analysis, or duplex-sensitive chromatography | Duplex formation and assembly consistency | Whether conjugation has disrupted the intended RNA architecture |
| Processing Behavior | Determine whether the construct releases or generates an RNAi-competent siRNA species | In vitro Dicer digestion, gel or LC analysis of cleavage products, time-course comparison | Cleavage pattern and processing efficiency | Whether the selected architecture supports the proposed intracellular mechanism |
| Cellular Uptake | Compare internalization in TLR9-positive and control cell models | Flow cytometry, microscopy, labeled-conjugate tracking, competition studies | Uptake level, cell selectivity, and localization trend | Whether CpG-associated uptake is adequate for functional testing |
| TLR9 Response | Measure whether the CpG domain retains the intended receptor-related activity | Reporter assays, pathway markers, cytokine panels, CpG-only comparison | Response magnitude and construct-dependent activity | Whether conjugation preserves or materially changes CpG function |
| Gene Silencing | Quantify target-specific RNAi after uptake and processing | RT-qPCR, digital PCR, immunoblotting, immunoassay, or project-specific protein readout | Target-mRNA and protein reduction relative to controls | Whether the construct produces sequence-dependent silencing |
| Specificity Controls | Separate CpG signaling, sequence effects, linker effects, and general oligonucleotide responses | Non-targeting conjugate, non-CpG conjugate, unconjugated mixture, receptor-control model | Mechanistic attribution across matched controls | Whether observed activity supports the intended dual-function mechanism |
Our workflow connects biological model selection with oligonucleotide chemistry, conjugate construction, analytical verification, and functional interpretation. Each step is designed to expose critical risks early and provide decision-ready outputs for research teams.
We define the target gene, species, TLR9-positive cell type, desired CpG behavior, preferred siRNA format, study scale, and required controls. This step determines whether the project is primarily a delivery study, a dual-function mechanism study, a Dicer-processing investigation, or a candidate-screening program.
CpG motif, backbone pattern, siRNA target site, strand polarity, duplex length, attachment position, linker concept, and chemical modifications are reviewed together. The client receives a proposed construct map and a control strategy before synthesis is authorized.
We confirm synthesis route, conjugation chemistry, purification approach, analytical panel, functional assays, material quantities, and reporting format. Alternative constructs can be included when attachment site, linker length, or CpG architecture requires side-by-side evaluation.
CpG ODN and siRNA components are synthesized with the required handles and modifications, followed by conjugate assembly, purification, desalting, and duplex annealing. Process choices are adjusted to the product's mixed DNA/RNA composition and junction chemistry.
Identity, purity, duplex integrity, and conjugate integrity are reviewed before functional work. Depending on scope, testing may examine stability, Dicer processing, uptake, TLR9-related response, target-mRNA reduction, protein knockdown, and performance relative to matched controls.
Final materials are delivered with sequence and modification maps, analytical results, handling guidance, and functional data where included. The project summary highlights remaining uncertainties, candidate-ranking logic, and practical next steps for optimization or expanded research.
CpG-siRNA programs succeed when immunostimulatory oligonucleotide design, RNAi chemistry, conjugation, and cell-model biology are managed as one development problem. Our service platform is structured to reduce disconnects between these workstreams and provide clearer evidence for construct selection.
CpG-siRNA conjugates are useful research tools when a project needs to connect TLR9-associated uptake or signaling with sequence-specific RNA interference. Our services support focused mechanism studies, candidate comparison, and delivery-platform research in carefully selected biological models.
Whether your team has a defined CpG and siRNA sequence or needs support building the complete construct, our specialists can coordinate design, synthesis, conjugation, purification, characterization, and functional research planning. We help identify the critical variables that should be resolved before material is produced, including species fit, TLR9-positive model selection, Dicer dependence, linker architecture, modification strategy, and control design. Contact us to discuss your CpG-siRNA conjugate requirements and receive a fit-for-purpose project plan.
CpG motifs are specifically recognized by TLR9 receptors expressed on immune cells, enabling receptor-mediated uptake without requiring additional transfection reagents for dendritic cells, macrophages and B cells.
TLR9-positive immune cells including dendritic cells, macrophages, and B cells demonstrate efficient uptake and gene silencing with CpG-siRNA conjugates in research applications.
Silencing efficacy is evaluated through mRNA quantification, protein expression analysis, and functional assays in relevant immune cell models to ensure target-specific knockdown.
Loading ......
